Pharmaceutical outsource services provider Brecon Pharmaceuticals has appointed Dr Susan Miles to its board as director, clinical trials services. She joined Brecon in February and was previously ceo of Quantum Research UK.
US biopharma company Arena Pharmaceuticals has appointed Dr Harry Hixson, Jr., and Dr Tina Nova to its board of directors. Dr Hixson is chairman and ceo of BrainCells, chairman of Sequenom and a board member of Discovery Partners International. Dr Nova is president, ceo and co-founder of Genoptix. She also co-founded Nanogen, where she previously served as coo and president.
Shaun Myers has joined Albion Chemicals Group as general manager of its Newcastle depot, where he will oversee Albion's sales and marketing operations. Myers was previously business development manager at David S Smith Packaging in Lockerbie.
Specialist company Warwick Effect Polymers (WEP), of Coventry in the UK, has appointed Thomas Neenan as vice president for business development in the US. He joins from Genzyme Drug Discovery and Development, where he was vice president for business operations.
Fergal O'Brien has also joined the company as its new ceo. He was formerly business development director with Dowpharma, of Cambridge in the UK, and has also worked for Celltech, Enzymatix, and Chiroscience in a variety of roles.
Freeman Technology, of Malvern in the UK, has appointed Dr Terry Cooper to the new position of sales director. He joins the company from Brewer Science, a US supplier of speciality materials and equipment to the semiconductor industry, where he headed the company's European operation. Prior to this, Cooper held senior management positions at Broner Engineering and also at Malvern Instruments.
Three senior appointments have been made recently by outsourcing service provider Penn Pharmaceutical Services, including a fifth QP.
Ex-Alpharma GMP co-ordinator Gaynor Langley joins as head of compliance. She is a Permanent QP, a Member of the Royal Society of Chemistry and an ISO lead assessor.
Ex-health & safety consultant Joanne Campbell joins Penn as a quality control analyst, and the business development team has been boosted by the addition of Matthew Lakelin from Ortho-Clinical Diagnostics.
Metabasis Therapeutics has appointmented William Rohn to the company's board of directors. Rohn, the chief operating officer of Biogen Idec, has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and, more recently, Biogen Idec.
Anadys Pharmaceuticals, a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines to treat chronic viral hepatitis and bacterial infections, has appointmented Dr Douglas Richman as chairman of its clinical and scientific advisory board. Dr Richman is a virologist and practicing physician with the Veterans Affairs San Diego Healthcare System and a Professor of Pathology and Medicine at the University of California, San Diego (UCSD) School of Medicine. He trained in infectious diseases and medical virology at Stanford, the National Institutes of Health (NIH) and Harvard.
Canadian biotech company Oncolytics Biotech has appointed Dr Matt Coffey as Chief Scientific Officer. Dr Coffey was formerly vice president of product development of Oncolytics.